Biogen Inc. $BIIB Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lifted its holdings in Biogen Inc. (NASDAQ:BIIB) by 1,648.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 103,677 shares of the biotechnology company’s stock after buying an additional 97,747 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Biogen were worth $18,246,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Advisory Services Network LLC increased its position in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares in the last quarter. CVA Family Office LLC increased its position in shares of Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 71 shares in the last quarter. Davis Investment Partners LLC increased its position in shares of Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 71 shares in the last quarter. Optas LLC increased its position in shares of Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 73 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its position in shares of Biogen by 8.1% in the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 89 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the subject of several recent research reports. HSBC increased their price objective on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research report on Tuesday, March 17th. Piper Sandler reissued an “overweight” rating and issued a $225.00 price objective (up from $214.00) on shares of Biogen in a research report on Friday, May 15th. Canaccord Genuity Group increased their price objective on shares of Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. BMO Capital Markets increased their price objective on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Finally, Morgan Stanley upped their target price on shares of Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $215.62.

Biogen Price Performance

Shares of BIIB stock opened at $187.80 on Thursday. The company has a market capitalization of $27.73 billion, a PE ratio of 20.15, a price-to-earnings-growth ratio of 1.68 and a beta of 0.19. The firm has a fifty day simple moving average of $185.39 and a 200-day simple moving average of $180.41. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.